Shanghai ZhenGe Biotech, a China CDMO, completed a $51 million Series A financing round led by Shanghai-based healthcare investment firm Lyfe Capita. The company will use the proceeds for additional hires and to expand its Shanghai R&D center

BeiGene, a Beijing cancer biopharma, announced a blockbuster collaboration with Amgen. I-Mab, a Shanghai biopharma, has filed to IPO; Aesthetic Medical International Holdings, a Shenzhen aesthetics company, completed a $30 million IPO on NASDAQ.